SCHEMBL23924049

SCHEMBL23924049

O=C(O)N[C@H]1C[C@H](Oc2cccnc2)C1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.51
GRIN1 Q05586 3/20 0.47
GRIN2B Q13224 3/20 0.47
CHRNB2 P17787 2/20 0.47
CHRNA4 P43681 2/20 0.47
NAAA Q02083 1/20 0.44
FFAR1 O14842 1/20 0.43
TNKS O95271 1/20 0.42
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
HRH3 Q9Y5N1 1/20 0.40
SPR P35270 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
KCNH2 Q12809 1/20 0.39
PLOD2 O00469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924051 1.00 EPHX2 (0.51) EPHX2GRIN1GRIN2BCHRNB2CHRNA4
SCHEMBL18530356 0.82 EPHX2 (0.47) EPHX2GRIN1GRIN2BTNKSPARP1
SCHEMBL18530449 0.82 EPHX2 (0.47) EPHX2GRIN1GRIN2BTNKSPARP1
SCHEMBL29900545 0.82 EPHX2 (0.44) EPHX2GRIN1GRIN2BCHRNB2CHRNA4
SCHEMBL23167627 0.82 EPHX2 (0.44) EPHX2GRIN1GRIN2BCHRNB2CHRNA4
SCHEMBL23167630 0.82 EPHX2 (0.44) EPHX2GRIN1GRIN2BCHRNB2CHRNA4
SCHEMBL23923871 0.80 GRIN1 (0.49) GRIN1GRIN2BOPRM1OPRK1KCNH2
SCHEMBL23923870 0.80 GRIN1 (0.49) GRIN1GRIN2BOPRM1OPRK1KCNH2
Hydrochloric Acid SCHEMBL28932922 0.77 EPHX2 (0.51) EPHX2GRIN1GRIN2BCHRNB2CHRNA4
SCHEMBL23924384 0.76 GRIN1 (0.48) EPHX2GRIN1GRIN2BCHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 EPHX2 2416/4885GRIN1 81/4885GRIN2B 80/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 EPHX2 2416/4885GRIN1 81/4885GRIN2B 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.